title: Relationship between weight change and glycaemic control in patients with type 2 diabetes receiving once-weekly dulaglutide treatment.
abstract: To assess the relationship between weight change and glycated haemoglobin (HbA1c) change in dulaglutide-treated patients by analysing data from six head-to-head phase III AWARD clinical trials.
  
  
  
  At 26 weeks, the relationship between weight and HbA1c was analysed in each trial rather than by pooling data because of differences in design and background therapy. The effect of baseline characteristics was also evaluated with regard to weight and HbA1c response.
  
  
  
  Across the studies, 87-97% and 83-95% of patients treated with dulaglutide 1.5 and 0.75 mg, respectively, had reductions in HbA1c levels, while 57-88% and 43-84% of patients treated with dulaglutide 1.5 and 0.75 mg, respectively, experienced weight loss. The majority (55-83%) of patients receiving dulaglutide 1.5 mg experienced weight loss and HbA1c reductions, while 41-79% of patients in the dulaglutide 0.75 mg arm lost weight and had reductions in HbA1c level. A weak and inconsistent correlation was observed between the changes in weight and HbA1c (range from -0.223 to 0.267) in patients treated with dulaglutide. The baseline characteristics of gender, age, duration of diabetes, HbA1c, body weight and BMI were not related to different combinations of weight and HbA1c responses.
  
  
  
  Dulaglutide is an effective treatment option across the type 2 diabetes treatment spectrum. Dulaglutide showed dose-dependent effects on both weight loss and HbA1c reduction. These effects had a weak correlation and appeared to be independent.
authors.affiliation: Division of Endocrinology, Emory University School of Medicine, Atlanta, GA, USA.
authors.forename: G E
authors.initials: GE
authors.lastname: Umpierrez
authors.affiliation: Department of Endocrinology, Cleveland Clinic, Cleveland, OH, USA.
authors.forename: K M
authors.initials: KM
authors.lastname: Pantalone
authors.affiliation: Lilly USA, LLC., Indianapolis, IN, USA.
authors.forename: A Y M
authors.initials: AY
authors.lastname: Kwan
authors.affiliation: Eli Lilly and Company, Indianapolis, IN, USA.
authors.forename: A G
authors.initials: AG
authors.lastname: Zimmermann
authors.affiliation: Eli Lilly and Company, Indianapolis, IN, USA.
authors.forename: N
authors.initials: N
authors.lastname: Zhang
authors.affiliation: Lilly USA, LLC., Indianapolis, IN, USA.
authors.forename: L
authors.initials: L
authors.lastname: Fernández Landó
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000187:drug effects* / Q000378:metabolism; D001835:Body Weight / Q000187:drug effects*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D004763:Glucagon-Like Peptides / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D007141:Immunoglobulin Fc Fragments / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome; D015431:Weight Loss / Q000187:drug effects
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007141:Immunoglobulin Fc Fragments; D011993:Recombinant Fusion Proteins; D004763:Glucagon-Like Peptides; C555680:dulaglutide
keywords: GLP-1 analogueincretin therapy; dulaglutide; incretin therapy; type 2 diabetes